This clinical trial is focused on the treatment of laryngeal leukoplakia, a condition characterized by white patches on the vocal cords, which can potentially lead to more serious health issues if left untreated. The study will explore the effectiveness of two medications: Diflucan (fluconazole) and Kefexin (cefalexin monohydrate). Diflucan is administered as a hard capsule, while Kefexin is provided as a film-coated tablet. Both medications are taken orally.

The purpose of this study is to determine whether these antimicrobial treatments can help in the disappearance of leukoplakia. Participants in the study will receive either one of the medications or a placebo. The study will last for a maximum of six months, during which participants will be monitored for changes in their condition.

Throughout the study, participants will be required to take the medication as prescribed and attend regular check-ups to assess their progress. The ultimate goal is to see if these treatments can effectively reduce or eliminate the white patches associated with laryngeal leukoplakia, thereby improving the health and quality of life for those affected by this condition.